Stockpolly
Search
Delisting risk
XCUR · NASDAQ · Biotechnology

Exicure (XCUR)

Develops burixafor for stem-cell mobilization before autologous transplant.

$1.36
Pre-market+0.04 (+3.40%)
At close$1.32(+1.54%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue001000000000
Cost of revenue000000000000
Gross profit001000000000
311138−332211
Research & development000000111100
211111221211
General & administrative211111221211
Other expenses110016−600000
Operating income−3−1−1−1−3−83−3−2−2−2−1
−200110000−100
Interest income000000000000
Interest expense000000000000
Other non-operating income200−1−20600100
Income before tax−5−1−1−1−1−73−3−2−4−2−1
Income tax expense000000000−100
Net income from continuing operations−5−1−1−1−1−73−3−2−3−2−1
Net income−5−1−1−1−1−73−3−2−3−2−1
EPS, basic−$0.61−$0.17−$0.10−$0.07−$0.15−$1.19$0.49−$0.41−$0.39−$0.45−$0.29−$0.18
EPS, diluted−$0.61−$0.17−$0.10−$0.07−$0.15−$1.19$0.49−$0.41−$0.39−$0.45−$0.29−$0.18
Weighted average shares, basic999976666666
Weighted average shares, diluted999976666666
EBITDA−5−1−10−1−7−3−2−2−3−2−1
Depreciation & amortization000000000000
EBIT−5−1−1−1−1−7−3−2−2−4−2−1